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Abstract
Epstein-Barr virus (EBV) is closely associated with nasopharyngeal carcinoma (NPC), a human malignancy notorious for its
highly metastatic nature. Among EBV-encoded genes, latent membrane protein 1 (LMP1) is expressed in most NPC tissues
and exerts oncogenicity by engaging multiple signaling pathways in a ligand-independent manner. LMP1 expression also
results in actin cytoskeleton reorganization, which modulates cell morphology and cell motility— cellular process regulated
by RhoGTPases, such as Cdc42. Despite the prominent association of Cdc42 activation with tumorigenesis, the molecular
basis of Cdc42 activation by LMP1 in NPC cells remains to be elucidated. Here using GST-CBD (active Cdc42-binding
domain) as bait in GST pull-down assays to precipitate active Cdc42 from cell lysates, we demonstrated that LMP1 acts
through its transmembrane domains to preferentially induce Cdc42 activation in various types of epithelial cells, including
NPC cells. Using RNA interference combined with re-introduction experiments, we identified FGD4 (FYVE, RhoGEF and PH
domain containing 4) as the GEF (guanine nucleotide exchange factor) responsible for the activation of Cdc42 by LMP1.
Serial deletion experiments and co-immunoprecipitation assays further revealed that ectopically expressed FGD4
modulated LMP1-mediated Cdc42 activation by interacting with LMP1. Moreover, LMP1, through its transmembrane
domains, directly bound FGD4 and enhanced FGD4 activity toward Cdc42, leading to actin cytoskeleton rearrangement and
increased motility of NPC cells. Depletion of FGD4 or Cdc42 significantly reduced (,50%) the LMP1-stimulated cell motility,
an effect that was partially reversed by expression of a constitutively active mutant of Cdc42. Finally, quantitative RT-PCR
and immunohistochemistry analyses showed that FGD4 and LMP1 were expressed in NPC tissues, supporting the potential
physiologically relevance of this mechanism in NPC. Collectively, our results not only uncover a novel mechanism underlying
LMP1-mediated Cdc42 activation, namely LMP1 interaction with FGD4, but also functionally link FGD4 to NPC
tumorigenesis.
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Introduction
Epstein–Barr virus (EBV) is a human c-herpesvirus that is
closely associated with many human malignancies, including
nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma, T-cell
lymphoma, and gastric carcinoma [1]. NPC, which is prevalent in
Taiwan and southeastern China, is a human squamous cell cancer
notorious for its highly metastatic nature [2]. In NPC, EBV
infection is predominantly latent and viral gene expression is
restricted. Among the expressed viral genes, latent membrane
protein 1 (LMP1) is detected in most NPC tissues [3]. LMP1 has
oncogenic properties to transform rodent fibroblast cell lines [4,5]
and promote cell growth in soft agar [6]. LMP1 is a 62-kDa
integral membrane protein composed of a short N-terminal
domain, six transmembrane domains, and a 200-amino-acid (aa)
cytoplasmic tail at the C-terminus [7]. By mimicking TNFR
(tumor necrosis factor receptor) family members, LMP1 through
its cytoplasmic tail engages TRAFs (TNFR-associated factors) and
TRADD (TNFR-associated death domain protein) to transduce
multiple signaling pathways, including nuclear factor-kappa B
(NF-kB)-mediated transcription [8] and the c-Jun amino-terminal
kinase (JNK) pathway [9,10]. Unlike TNFR-based signaling,
however, LMP1 appears to signal in a ligand-independent fashion
relying on its N-terminus and transmembrane domains to self-
associate in the lipid rafts [11–13]. As a result, LMP1 is a
constitutively active receptor [14–16].
In addition to growth transformation, LMP1 has also been
linked to regulation of the actin cytoskeleton. In lymphocytes,
LMP1 expression leads to the formation of membrane protrusions
and membrane ruffling, which involve actin reorganization [5]. In
Swiss 3T3 fibroblasts, LMP1 is capable of inducing the assembly of
actin-rich surface protrusions called filopodia [17]. Moreover, the
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002690LMP1-induced formation of filopodia in fibroblasts can be
abolished by a dominant-negative mutant of Cdc42, a member
of the Rho (Ras-homology) GTPase family [17], implying that
LMP1 is capable of activating Cdc42. Rho GTPases, mainly
comprising members of the Cdc42, Rac and Rho subfamilies,
actively regulate various actin-dependent functions such as cell
migration, adhesion, cytokinesis, axon guidance, and phagocytosis
in all eukaryotic cells [18]. Cdc42 in particular is well known to
regulate actin filament (F-actin) organization and vesicle trafficking
[19–21]. Like all GTPases, Cdc42 acts as a binary switch cycling
between an inactive (GDP-bound) and an active (GTP-bound)
conformational state. The activation of Cdc42 is mediated by
guanine nucleotide exchange factors (GEFs), which convert the
GDP-bound form of Cdc42 to the GTP-bound form [20,22,23].
Activated Cdc42, in turn, binds to its downstream effectors, such
as the Wiskott-Aldrich syndrome protein (WASP) [24,25], through
which it ultimately generates a variety of cellular effects [26,27].
Not surprisingly, given the prominent role of Cdc42 in so many
aspects of cell biology, aberrant activation of Cdc42 (or
dysfunction of Cdc42 GEFs) results in pathogenesis, including
tumorigenesis and tumor progression, cardiovascular diseases,
diabetes, and neuronal degenerative diseases [28,29].
FGD4 (FYVE, RhoGEF and PH domain-containing 4), also
known as Frabin (FGD1-related F-actin binding protein), like
FGD2 and FGD3, is a Cdc42-specific GEF that shows significant
sequence homology to FGD1, which was originally discovered by
positional cloning as the gene responsible for a human X-linked
skeletal disease called faciogenital dysplasia [30–33]. It has been
revealed that mutations in the gene encoding FGD4 cause an
inherited neurological disease commonly referred to as Charcot-
Marie-Tooth (CMT) disease, a type of hereditary motor and
sensory neuropathy [34]. All FGD proteins possess a similar
domain organization, whereas each FGD has a unique N-terminal
region [35]. FGD4 consists of an N-terminal FAB (F-actin-
binding) domain, a DH (Dbl homology) domain containing the
principal GEF catalytic unit, and multiple phosphoinositide-
binding domains, including two PH (pleckstrin homology)
domains and an FYVE (Fab1, YOTB, Vac1, and EEA1) domain
at the C-terminus [30,35]. Accordingly, FGD4 likely couples the
actin cytoskeleton to the cellular membrane by localization to the
membrane and simultaneously binding F-actin. In fibroblasts, it
has been shown that rat Fgd4 binds along the sides of F-actin
through the FAB domain and directly induces activation of Cdc42
in the vicinity of actin structures, resulting in actin reorganization
[30]. However, the mechanisms by which external or internal
stimuli transduce the signals to activate FGD4 largely remain
unclear.
In the present study, we sought to investigate the activation of
Cdc42 by LMP1 in NPC cells, which are physiologically relevant
to EBV. Importantly, we uncovered a novel mechanism under-
lying LMP1-mediated Cdc42 activation, showing that LMP1
physically interacts with FGD4, leading to functional consequenc-
es associated with NPC tumorigenesis and tumor progression.
Results
LMP1 preferentially induces Cdc42 activation in epithelial
cells
To assess the effect of LMP1 on Cdc42 activation in cells, we
carried out GST-pull-down assays using GST-CBD (containing
the active Cdc42-binding domain of WASP) as bait to precipitate
active Cdc42 in lysates of 293 Tet-On cells, in which the
expression of LMP1 was induced by doxycycline (Dox). As shown
in Figure 1A, LMP1 expression led to a 4.8-fold increase in the
level of active Cdc42 compared with the control without affecting
total Cdc42 expression levels. Moreover, LMP1-mediated Cdc42
activation was specific since activation of Rac1 and RhoA, two
related members of Rho GTPase family, was not significant.
To corroborate these phenomena in EBV-associated cells, we
conducted similar GST pull-down assays using nasopharyngeal
epithelial cells (NP69) and four NPC cell lines, each of which
expressed LMP1 or empty vector (control). Consistent with the
results obtained in 293 Tet-On cells, LMP1 expression led to a
3.3-fold increase in active Cdc42 in NP69 cells (Figure 1B), and
induced 4.6-, 6.7-, 10.2-, and 10.6-fold increases in active Cdc42
in four tested NPC cell lines (TW02, TW01, TW04, and TW06),
respectively (Figure 1C). In contrast, there was no evidence for
Rac1 or RhoA activation by LMP1 in NP69 cells or NPC cells
(Figure 1B and 1C). Collectively, these results demonstrate that
LMP1 preferentially induces Cdc42 activation in various types of
epithelial cells.
LMP1 transmembrane domains are required for Cdc42
activation
To dissect the functional domains of LMP1 responsible for its
activation of Cdc42, we generated a series of LMP1 deletion
constructs (Figure 2A) and examined their effects on Cdc42
activation in NPC cells. Deletion mutants lacking transmembrane
domains 3 and 4 (DTM3/4) or 3–6 (DTM3–6) exhibited
substantially impaired ability to activate Cdc42, producing 3.1-
and 3.5-fold increases, respectively, compared to the 9.7-fold
increase induced by full-length LMP1 (Figure 2B). In contrast,
deletion of the entire C-terminal cytoplasmic tail (DCT) of LMP1
did not interfere with Cdc42 activation (a 9.3-fold vs. a 9.7-fold
increase), indicating that C-terminus-dependent LMP1-trans-
duced signaling pathways are not involved in this event. To
confirm the importance of the transmembrane domains of LMP1
in Cdc42 activation, we replaced this region with the transmem-
brane domain of a TNFR member, CD40 (denoted CD40CT in
Figure 2A). As shown in Figure 2C, the resulting chimera failed to
activate Cdc42 (1.3-fold increase vs. 7.0-fold increase for chimeric
and wild-type LMP1, respectively), indicating that the transmem-
brane domains of LMP1 are required for Cdc42 activation. To
verify whether the LMP1-induced activation of Cdc42 was
associated with remodeling of the actin filaments, we next
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Epstein-Barr virus (EBV) is closely associated with human
malignancies, including nasopharyngeal carcinoma (NPC).
Among EBV-expressed genes, latent membrane protein 1
(LMP1) has been detected in most NPC tissues and has the
ability to transform cell growth and drive cell migration,
both of which are highly associated with tumorigenesis
and tumor progression. Previous reports have demon-
strated that cell migration primarily involves cytoskeleton
rearrangement, and the RhoGTPase Cdc42 is known to
actively mediate such rearrangement processes. Using
LMP1-expressing NPC cells, we discovered that LMP1
induces Cdc42 activation by directly binding to FGD4, a
positive regulator of Cdc42, thereby promoting motility of
NPC cells. The observed correlation between FGD4 and
LMP1 expression in NPC tissues provides support of
physiological relevance. Notably, FGD4 has recently been
shown to be responsible for a type of inherited neural
disease. Our findings not only provide a novel insight into
EBV pathogenesis, but also suggest a role for FGD4 in
tumorigenesis.
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expressed Flag-LMP1 or its various transmembrane domains-
truncated forms. As shown in Figure 2D, expression of Flag-LMP1
and its C-terminus-deleted form (DCT) led to formation of
microspike-like actin structures (filopodia) at the plasma membrane
and actin bundles at the perinuclear regions (Golgi apparatus). In
contrast, expression of the transmembrane domains-truncated form
DTM3/4 or DTM3–6, or the chimera CD40CT failed to induce
the actin remodeling as described above. The truncated form
DTM1/2 remained a moderate ability for the actin remodeling
compared to the DTM3–6 or the CD40CT chimera, correlating
with the extent of Cdc42 activation.
Since the transmembrane domains confer properties on LMP1
that distinguish it from TNFR family members [13,14], we next
investigated whether the TNFR members, TNFR and IL-1R
(interleukin-1 receptor), were capable of activating Cdc42 in NPC
cells. Compared with vehicle controls, treatment of NPC cells with
the TNFR ligand TNF-a (50 or 100 ng/ml) or the IL-1R ligand IL-
1a (10 ng/ml) for 30 min had little effect on Cdc42 activation
(Figure S1A) and on actin remodeling (Figure S1B). While NPC
cells seemed to be insensitive to IL-1a induction of NF-kB signaling,
positive controls showed that TNF-a induced degradation of
inhibitor kappa B (IkBa) protein (Figure S1A) and subsequent
nuclear translocation of a NF-kB subunit p65 (Figure S1B),
indicating activation of NF-kB signaling [36] and confirming the
functional integrity of TNF-a in this experimental setting. These
data conclusivelydemonstrated thattheactionofLMP1 wasdistinct
from that of TNFR with respect to Cdc42 activation in NPC cells.
LMP1 appears to induce Cdc42 activation at LMP1-
resident sites
To better elucidate the nature of LMP1-mediated Cdc42
activation, we sought to dissect the spatial pattern of Cdc42
Figure 1. LMP1 preferentially induces Cdc42 activation in epithelial cells. (A) 293 Tet-On cells were treated with 5 mg/ml doxycyclin (Dox)
for 24 h to induce LMP1 expression. After a 6-h serum starvation, cells were lysed and the lysates were incubated with immobilized GST-CBD (active
Cdc42-binding domain of WASP), GST-PBD (active Rac1-binding domain of PAK1), or GST-RBD (active RhoA-binding domain of Rhoteckin) at 4uC for
1 h to pull down the active form of Cdc42, Rac1, or RhoA in cells. Details are provided in Materials and Methods. Total (input) and active (GTP-bound)
levels of Cdc42, Rac1, or RhoA were analyzed by Western blotting with the respective antibody. Numbers represent relative fold-changes of GTPase
activation determined based on densitometric quantitation. The trace in the absence of LMP1 was set as 1. The constant amounts of GST-fusion
proteins for pull-down assays were shown by Ponceau S staining. (B) Cell lysates from NP69 cells (denoted C) or stable LMP1-expressing NP69 cells
(denoted L) incubated in serum-free media for 6 h were harvested for GST pull-down assays, and levels of active Cdc42, Rac1, and RhoA were
assessed as described above. (C) A variety of NPC cell lines, NPC-TW01, -TW02, -TW04, and -TW06, were transfected with an LMP1 expression plasmid
or empty vector (control) and incubated for 24 h. Following a 6-h serum starvation, cells were lysed and the lysates were applied to GST pull-down
assays. The resulting products were analyzed for active Cdc42, Rac1, and RhoA, as described above.
doi:10.1371/journal.ppat.1002690.g001
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PLoS Pathogens | www.plospathogens.org 3 May 2012 | Volume 8 | Issue 5 | e1002690Figure 2. The transmembrane domains of LMP1 are required for induction of Cdc42 activation and the associated F-actin
rearrangement. (A) Schematic illustrations of Flag-tagged LMP1 and its truncated derivatives. FL, full-length LMP1; DCT, deletion of the C-terminus;
DTM1/2, deletion of transmembrane domains 1 and 2; DTM3/4, deletion of transmembrane domains 3 and 4; DTM3–6, deletion of transmembrane
domains 3–6. CD40CT indicates that the entire transmembrane region of LMP1 (aa 1–177) is replaced with that of CD40 (aa 1–214). (B) NPC-TW04
cells that had been transfected with 1 mg of plasmid encoding Flag-LMP1 or its truncated versions were grown for 24 h, followed by serum starvation
for 6 h. Then cell lysates were harvested for GST pull-down assays using GST-CBD beads as bait (detailed in Materials and Methods) to pull-down
active (GTP-bound) Cdc42 in cells. The resulting products were analyzed by Western blotting with an anti-Cdc42 antibody. The levels of active Cdc42
were quantified as described above. The trace in the absence of LMP1 was set as 1. The constant amounts of GST-CBD used in pull-down assays were
shown by Ponceau S staining. (C) NPC-TW04 cells that had been transfected with 1 mg of plasmid encoding Flag-LMP1 or the chimera CD40CT were
lysed after incubation as described above. Cell lysates were harvested for GST-CBD pull-down assays, and the level of active Cdc42 was determined as
described above. (D) Induction of F-actin rearrangement by LMP1. NPC-TW04 cells that had been grown on poly-L-lysine-coated coverslips overnight
were transfected with 0.5 mg of plasmid encoding Flag-tagged full-length, truncated, or chimeric LMP1, and then incubated for 24 h. Following a 6-h
serum starvation, cells were fixed and permeabilized, followed by subsequent staining with primary anti-Flag (M2) and FITC-conjugated secondary
antibodies. For actin filament (F-actin) staining, cells were co-stained with TRITC-conjugated phalloidin. Images were acquired using a ZEISS LSM510
confocal microscope as detailed in Materials and Methods. Scale bars, 20 mm. Transfection of an empty vector had no effect on actin organization
(data not shown).
doi:10.1371/journal.ppat.1002690.g002
LMP1 Activates Cdc42 Through Interaction with FGD4
PLoS Pathogens | www.plospathogens.org 4 May 2012 | Volume 8 | Issue 5 | e1002690activation upon LMP1 expression. For this aim, we generated an
EGFP-CBD construct containing the active Cdc42-binding
domain of WASP to locate active Cdc42 inside cells. Following
transfection of 293 Tet-On cells with pEGFP-CBD, LMP1
expression was induced by doxycycline (Dox) and cells were
analyzed by confocal microscopy. As shown in Figure S2A (upper
panel), LMP1 expression led to EGFP-CBD co-distribution at
LMP1-resident sites (i.e., Golgi apparatus and plasma membrane).
In contrast, a more homogenous distribution of EGFP-CBD was
evident in cells in which LMP1 expression was not induced
(bottom panel), implying Cdc42 activation at LMP1-resident sites.
We next verified whether LMP1 expression resulted in distribution
of Cdc42 to LMP1-resident sites using NPC cells expressing
EGFP-LMP1 or the truncated form DTM3–6. As shown in Figure
S2B, a portion of Cdc42 was co-distributed with EGFP-LMP1 (the
inset) rather than with the DTM3–6 form in NPC cells. These data
suggest the possibility that certain factors that act upstream of
Cdc42-activation cascades may co-localize with LMP1 and
participate in this event.
FGD4 is the GEF responsible for LMP1-mediated Cdc42
activation
On the basis of the above observation (Figures 2 and S2) and the
preferential activation of Cdc42 by LMP1 (Figure 1), we
hypothesized that LMP1 modulates a Cdc42 GEF and thereby
activates Cdc42. To verify this, we first surveyed the literature for
candidate Rho GEFs that show specificity toward Cdc42 and
localize to the Golgi apparatus and the plasma membrane, where
LMP1wasexpressedaswell(Figure2E).A subset ofGEFsthatmeet
such criteria, including FGD1 [37], FGD3 [32], FGD4 [38],
intersectin-1(ITSN1) [39], and DOCK9(zizimin)[40], was selected
for further evaluation. The expression of these GEFs at the
transcriptional level was validated in NPC cells using quantitative
reverse transcription-polymerase chain reaction (RT-PCR; data not
shown). To evaluate the effects of these GEFs on LMP1-mediated
Cdc42 activation, we performed RNA interference using small
interfering RNA (siRNA) to deplete each GEF from LMP1-
expressing NPC cells, followed by precipitation of active Cdc42, as
described above. The knockdown efficiency of each siRNA toward
its targeted GEF was analyzed by quantitative RT-PCR (Figure
S3A) and Western blotting. As shown in Figure 3A, knockdown of
FGD4 (siFGD4) reduced the LMP1-induced Cdc42 activation from
the 2.3-fold increase observed in control siRNA (siCtrl)-treated cells
to a 0.8-fold increase. In contrast, knockdown of each of the other
GEFs had little effect on LMP1-induced Cdc42 activation. A
quantitative analysis of data from five independent experiments
further reinforced the inhibitory effect of FGD4 knockdown on
LMP1-induced Cdc42 activation (Figure 3B). To reproduce the
phenomenon in epithelial cells other than NPC cells, we carried out
similar knockdown experiments using 293 Tet-On cells with or
without Dox induction. As shown in Figure 3C, knockdown of
FGD4 consistently reversed LMP1-mediated Cdc42 activation,
reducing the fold-increase from 2.3 to 0.5, indicating that this effect
was not restricted to NPC cells.
To reinforce the functional role of FGD4, we re-introduced
FGD4 expression by ectopically expressing FGD4 (Myc-FGD4) in
FGD4-depleted NPC cells that co-expressed LMP1, and then
assessed the activation of Cdc42 by LMP1. As shown in Figure 3D,
depletion of FGD4 consistently eliminated LMP1-mediated Cdc42
activation, reducing Cdc42 activation from a 3.0-fold increase to a
1.0-fold increase. In contrast, re-introduction of FGD4 expression
attenuated this reduction, limiting it to a 2.2-fold increase.
Collectively, these results confirm that FGD4 indeed plays a role
in the activation of Cdc42 by LMP1. As noted, FGD4 depletion
had no effect on the basal level of Cdc42 activation in cells lacking
LMP1 (Figure 3). Accordingly, the data demonstrate that FGD4 is
primarily involved in mediating LMP1-induced Cdc42 activation.
FGD4 modulates LMP1-induced Cdc42 activation
through protein-protein interaction
What little has been learned to date about the function of FGD4
has mainly been gleaned from experiments involving manipulation
of rat Fgd4 [30,35,38,41]. Despite the high sequence homology
between rat Fgd4 and human FGD4 (Figure S3B), it is uncertain
whether the functions of both proteins are identical. To
characterize the function of human FGD4 in NPC cells, we
generated a series of truncated human FGD4 constructs
(Figure 4A) to examine their effects on Cdc42 activation
(Figure 4B–4D) and actin remodeling (Figure S4A). As shown in
Figure 4B, expression of Myc-FGD4 (FL) activated Cdc42
compared with the vector control, increasing the level of active
Cdc42 by 3.3- (right panel) and 7.8-fold (left panel) in two different
experiments. The immunofluorescence staining revealed that
expression of Myc-FGD4 induced filopodia formation at the
plasma membrane (Figure S4A). Deletion of the FAB domain
(DFAB) of FGD4 did not affect the activation of Cdc42 (Figure 4C)
and the induction of filopodia (Figure S4A). In contrast, deletion of
the DH domain (DDH vs. FL; PH1–2 vs. DFAB) substantially
impaired the activity of FGD4 toward Cdc42 (Figure 4B and 4C)
as well as induction of actin remodeling (Figure S4A) and
recruitment of Cdc42 (Figure S4B), indicating that the DH
domain is essential for a full FGD4 activity. Moreover, deletion of
the PH1-to-PH2 domains (denoted FAB–DH) caused a functional
impairment of FGD4 (Figures 4B, 4C, and S4A) but left its ability
to recruit Cdc42 unchanged (Figure S4B), suggesting some aspect
of the function of PH1-to-PH2 domains, such as membrane
targeting, is also needed for a full FGD4 activity.
To investigate how FGD4 affects LMP1-mediated Cdc42
activation, we assessed the activation of Cdc42 by LMP1 in NPC
cells expressing LMP1 together with various forms of FGD4. As
shown in Figure 4B, ex‘pression of LMP1 alone led to activation of
Cdc42 compared with vector-transfected cells, increasing active
Cdc42 levels by 5.1- (right panel) and 8.7-fold (left panel) in two
different experiments. Co-expression of LMP1 with the full-length
FGD4 and with the DFAB form further augmented LMP1-
mediated Cdc42 activation by 1.2- and 1.3-fold, respectively
(Figure 4B), in agreement with the intact activities of these FGD4
proteins (Figure 4C). In contrast, co-expression of LMP1 with the
truncated forms of FGD4 that exhibited impaired FGD4 activities
(DDH, PH1–2, and FAB–DH) instead reduced LMP1-mediated
Cdc42 activation on average by 62%, 50%, and 39%, respectively
(Figure 4D), revealing that FGD4 indeed acts downstream of LMP1
to modulate Cdc42 activation.
On the basis of the known ability of PH domains to bind to
phosphoinositides as well as proteins [42,43] and our observation
that LMP1-mediated Cdc42 activation occurred at LMP1-resident
sites (Figure S2), we speculated that LMP1 likely interacted with
FGD4. To verify the interaction between LMP1 and FGD4, we
performed co-immunoprecipitation assays using NPC cells co-
expressing LMP1 and various forms of FGD4. As shown in
Figure 4E, LMP1 was co-precipitated with full-length, DFAB, and
DDH forms of FGD4, indicating that LMP1 interacted with
FGD4 in a manner that did not require FAB or DH domains.
Consistent with this, the FAB–DH form showed an impaired
ability to interact with LMP1, in contrast to the PH1–2 form,
which was sufficient for interaction with LMP1. Collectively, these
results revealed that the PH1-to-PH2 domains of FGD4 are
mainly responsible for the interaction of FGD4 with LMP1.
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interaction with FGD4 and the promotion of FGD4
activity
To corroborate the impact of the LMP1-FGD4 interaction on
LMP1 activation of Cdc42, we next examined if the transmem-
brane domains of LMP1, which were necessary for inducing
Cdc42 activation (Figure 2B and 2C), were responsible for the
interaction with FGD4. To accomplish this, we performed co-
immunoprecipitation assays using anti-Myc affinity resins to
precipitate Myc-FGD4-associated protein complexes in lysates of
NPC cells co-expressing Myc-FGD4 plus Flag-LMP1 or its
chimera, CD40CT. As shown in Figure 4F, wild-type LMP1 but
Figure 3. FGD4, a Cdc42 GEF, is involved in LMP1-mediated Cdc42 activation. (A) Identification of FGD4 as a GEF candidate involved in
LMP1-mediated Cdc42 activation in NPC cells. The potential GEF involved in the activation of Cdc42 by LMP1 was identified by co-transfecting NPC-
TW04 cells with 1 mg of Flag-LMP1 expression plasmid or empty vector (control), and siRNAs (25 mM) directed against DOCK9 (siDock9), intersectin-1
(siITSN1), FGD4 (siFGD4), FGD1 (siFGD1), FGD3 (siFGD3) or non-targeting control (siCtrl). Following a 6-h serum starvation at 48 h post-transfection,
cells lysates were harvested for GST-CBD pull-down assays. The knockdown efficiency for individual GEFs was analyzed by Western blotting with the
respective antibody. The level of active Cdc42 was determined as described above. The constant amounts of GST-CBD for pull-down assays were
shown by Ponceau S staining. The results shown are representative of five independent experiments. Quantitative data are shown in B. The relative
fold-changes in active Cdc42 are presented as means 6 SDs (*P=0.0052; paired t-test). (C) Confirmation of FGD4 involvement in 293 Tet-On cells. 293
Tet-On cells that had been transfected with 25 mM control or FGD4 siRNA and incubated for 24 h were further treated with Dox (5 mg/ml) for 24 h to
induce LMP1 expression. Cell extracts were then harvested for GST-CBD pull-down assays and the level of active Cdc42 was determined as described
above. (D) Normalizing the reduced levels of active Cdc42 in FGD4-depleted cells by re-introduction of FGD4. NPC-TW04 cells were co-transfected
with 25 mM control or FGD4 siRNA, together with 1 mg of Flag-LMP1 expression plasmid or empty vector (control), plus 2 mg of pMyc-FGD4
expression plasmids or Myc vector. Following a 6-h serum starvation at 48 h post-transfection, cells lysates were harvested for GST-CBD pull-down
assays, and the level of active Cdc42 was analyzed as described above.
doi:10.1371/journal.ppat.1002690.g003
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PLoS Pathogens | www.plospathogens.org 6 May 2012 | Volume 8 | Issue 5 | e1002690Figure 4. FGD4 modulates LMP1-mediated Cdc42 activation through protein-protein interaction. (A) Schematic illustrations of Myc-
tagged FGD4 and its truncated derivatives. FL, full-length FGD4; DFAB, deletion of the F-actin-binding domain; DDH, deletion of the Dbl homology
domain (catalytic domain); PH1 and PH2, pleckstrin homology domains 1 and 2; FYVE, a zinc finger domain named after Fab1, YOTB, Vac1, and EEA1.
(B) Characterization of FGD4 function and its effect on LMP1-mediated Cdc42 activation. NPC-TW01 cells were co-transfected with 1.5 mg of Myc-
FGD4 expression plasmids and 1 mg of Flag-LMP1 expression plasmid or empty vector (control). After 24-h incubation and a following 6-h serum
starvation, cells were lysed for GST-CBD pull-down assays and the level of active Cdc42 was determined as described above. The constant amounts of
GST-CBD for pull-down assays were shown by Ponceau S staining. The domain of FGD4 required for Cdc42 activation was determined by calculating
the relative fold-change in active Cdc42 with expression of truncated FGD4 versus expression of full-length FGD4. The mean 6 SD of five
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the transmembrane domains of LMP1 are required for its
interaction with FGD4. To explore the role of this protein-protein
interaction in FGD4 activity, we assessed Cdc42 activation by
Myc-FGD4 in the presence of LMP1 or CD40CT. The results
showed that co-expression of Myc-FGD4 with LMP1 increased
the level of active Cdc42 by 1.8-fold compared with expression of
FGD4 alone (Figure 4F). In contrast, co-expression of FGD4 with
CD40CT did not promote Cdc42 activation (1.1-fold). Taken
together, these data revealed that LMP1 interacts with and
coordinates the activity of FGD4.
To investigate whether Myc-FGD4 was co-precipitated with
LMP1 in a reciprocal way, we conducted co-immunoprecipitation
assays using anti-Flag affinity resins to precipitate Flag-LMP1-
associated protein complexes in lysates of NPC cells co-expressing
Myc-FGD4 with various forms of LMP1. As shown in Figure 5A,
Myc-FGD4 was co-precipitated with Flag-LMP1 but not with the
CD40CT chimera, consistent with the result shown in Figure 4F.
In contrast, Myc-FGD4 was not co-precipitated with the truncated
form DTM3/4 or DTM3–6, indicating that the transmembrane
domains 3 and 4 were the minimal region required for LMP1
interaction with FGD4. Moreover, deletion of the short N-
terminal domain (DNT) did not affect LMP1 co-precipitation of
Myc-FGD4 (Figure 5A). We next corroborate the interaction
between endogenous FGD4 and LMP1 by co-immunoprecipita-
tion assays using NPC cells expressing various forms of LMP1.
The resulting cell lysates were subsequently incubated with an
anti-FGD4 antibody coupled with protein G beads to precipitate
endogenous FGD4. As shown in Figure 5B, Flag-LMP1 was co-
precipitated with FGD4, indicating a physical interaction between
FGD4 and LMP1. Notably, neither the CD40CT chimera nor the
LMP1 truncated form lacking the transmembrane domains 3 and
4( DTM3/4 and DTM3–6) could be detected in the FGD4-
associated protein complexes, confirming the observation that
LMP1 mainly relies on its transmembrane domains 3 and 4 to
interact with FGD4.
LMP1 directly interacts with FGD4
To further investigate whether LMP1 directly interacted with
FGD4, we conducted in vitro affinity chromatography assays using
GST-FGD4 as bait to precipitate in vitro-translated, [
35S]methio-
nine-labeled LMP1. As shown in Figure 5C, in vitro-translated,
[
35S]methionine-labeled LMP1 was precipitated by GST-FGD4,
indicating a direct interaction between LMP1 and FGD4.
To buttress the direct interaction between LMP1 and FGD4
within live cells, we carried out an advanced bioluminescence
resonance energy transfer (BRET
2) assay using NPC cells. This
technology uses Renilla luciferase (Rluc) as the donor molecule and
a GFP
2 as the acceptor molecule in an assay analogous to
fluorescence resonance energy transfer (FRET) but without the
need for the use of an excitation light source. As shown in
Figure 5D, the BRET signal was evident in cells co-expressing
Rluc-LMP1 and GFP





0.016, and 0.004, respectively, vs. Rluc-LMP1/GFP
2-FGD4).
Moreover, expression of Flag-LMP1 in combination with Rluc-
LMP1/GFP
2-FGD4 competitively decreased the BRET ratio
(P=0.004; paired t-test), providing evidence for specificity.
LMP1 transmembrane domains are required for its co-
localization with FGD4, the redistribution of actin, and
the promotion of NPC cell motility
To investigate whether LMP1 affected the localization of FGD4
through protein-protein interaction, we performed subcellular
fractionation using postnuclear extracts of NPC cells expressing
LMP1 or the DTM3–6 form (Figure 5E), and performed immuno-
fluorescence staining of FGD4 using NPC cells expressing various
forms of LMP1 (Figure 6A). As shown in Figure 6A, LMP1
appeared to recruit a fraction of FGD4 to the perinuclear regions
(Golgi apparatus) where LMP1 was localized, compared to a
primary cytoplasmic localization of FGD4 in control vector-
transfected cells (data not shown). In contrast, replacement
(CD40CT) or deletion of the transmembrane domains (in
particular DTM3/4 and DTM3–6) of LMP1 substantially
impaired its co-localization with FGD4. Moreover, expression of
full-length LMP1 led to FGD4 redistribution from fractions 2–5 to
fractions 2–9 compared with the vector-expressing cells
(Figure 5E); however, expression of the DTM3–6 form appeared
not to result in this redistribution, suggesting that LMP1
interaction with FGD4 affects the intracellular distribution of
FGD4. Concomitantly, LMP1 expression led to a notable
redistribution of b-actin (a component of F-actin) from fractions
1–18 to fractions 1–28 (Figure 5E), implying a rearrangement of
actin filaments. In contrast, expression of the DTM3–6 had no
effect on this event, agreeable with the immunofluorescence
staining data in Figure 2D. This redistribution was not due to a
general alteration of protein localization, because the distribution
of caveolin-1 (CAV1) was comparable in all examined cells. While
efforts to detect traces of Cdc42 in all fractions were not successful,
these data functionally linked the LMP1-FGD4 interaction with
actin redistribution, suggesting that LMP1 induces actin rear-
rangement by enhancing FGD4 activity toward Cdc42.
To investigate whether the above events contributed to cell
motility, we conducted transwell migration assays using NPC cells
expressing various forms of LMP1. As shown in Figure 6B, LMP1
expression clearly induced cell motility compared with the vector
control (P,0.001; paired t-test); however, deletion of the
transmembrane domains apparently impaired this ability of
LMP1 (P,0.01; paired t-test). Moreover, the CD40CT chimera
failed to induce cell motility compared with the vector control
(P,0.005; paired t-test), correlating with its eliminated activation
of Cdc42 (a 0.6-fold increase; Figure 6C).
FGD4 and Cdc42 coordinate for LMP1-induced actin
rearrangement and cell motility
Toverifythe requirementofFGD4 and Cdc42inLMP1-induced
actin rearrangement, we used RNA interference to deplete FGD4
or Cdc42 from NPC cells, followed by expression of GFP-LMP1
and staining for F-actin. As shown in Figure 7A, expression of
independent experiments is shown in C (*, P,0.001; paired t-test). The effect of FGD4 on LMP1-mediated Cdc42 activation was demonstrated by
calculating the relative fold-change in active Cdc42 with expression of both LMP1 and FGD4 versus expression of LMP1 alone (B; numbers in italics).
The mean 6 SD of five independent experiments is shown in D (*P,0.05, **P,0.01; paired t-test). (E) Co-immunoprecipitation of Flag-LMP1 with
Myc-FGD4. NPC-TW01 cells that had been transfected with the indicated plasmids were lysed after incubation as described in B. The resulting cell
lysates were applied to co-immunoprecipitation assays with an anti-Myc affinity matrix. The precipitated protein complexes were analyzed by
Western blotting with anti-LMP1 (S12) and anti-Myc (9E10) antibodies. (F) NPC-TW01 cells that had been transfected with plasmids encoding Flag-
LMP1 or Flag-CD40CT together with Myc-FGD4 were lysed after incubation as described in B. A portion of the resulting cell lysate was analyzed by co-
immunoprecipitation assays using an ani-Myc affinity matrix and the remainder was analyzed by GST-CBD pull-down assays, as described above.
doi:10.1371/journal.ppat.1002690.g004
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PLoS Pathogens | www.plospathogens.org 8 May 2012 | Volume 8 | Issue 5 | e1002690Figure 5. LMP1 via its transmembrane domains 3 and 4 interacts with FGD4 and leads to redistribution of actin. (A) Co-
immunoprecipitation of Myc-FGD4 with Flag-LMP1. NPC-TW04 cells were co-transfected with 2 mg of expression plasmids for Myc-FGD4 plus 1.5 mg
of expression plasmids for Flag-tagged full-length, truncated, or chimeric LMP1. Cells were lysed at 24 h post-transfection, and the resulting cell
lysates were analyzed by co-immunoprecipitation assays using an anti-Flag affinity matrix. Details are provided in Materials and Methods. After an
overnight incubation at 4uC, the precipitated protein complexes were analyzed by Western blotting using anti-Myc and anti-Flag antibodies. (B) Co-
immunoprecipitation of Flag-LMP1 with endogenous FGD4. NPC-TW04 cells transfected with 2 mg of expression plasmids for Flag-LMP1, its truncated
forms, or CD40CT chimera were lysed at 24 h post-transfection. The resulting cell lysates were analyzed by co-immunoprecipitation assays using anti-
FGD4 antibodies coupled with protein G beads. Details are provided in Materials and Methods. After an overnight incubation at 4uC, the precipitated
protein complexes were analyzed by Western blotting using anti-FGD4 and anti-LMP1 antibodies. (C) In vitro binding of LMP1 to FGD4. Equal
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NPC cells resulted in filopodia formation at the plasma membrane.
In contrast, knockdown of either FGD4 or Cdc42 led to the
disappearance of such actin substructures resulting from GFP-
LMP1 expression, demonstrating the equivalent roles of FGD4 and
Cdc42 in LMP1-induced actin rearrangement.
amounts of in vitro-translated, [
35S]methionine-labeled LMP1 proteins were incubated with immobilized GST or GST-FGD4, as detailed in Materials
and Methods. The bound LMP1 proteins were resolved by SDS-PAGE followed by autoradiography. The amounts of GST-fusion proteins (arrowhead)
were determined by Coomassie blue staining. (D) Detection of a direct interaction between LMP1 and FGD4 in living cells using BRET
2 assays. BRET
2
ratios were measured in NPC-TW04 cells expressing the indicated constructs. Cells were detached at 24 h post-transfection and analyzed by BRET
2
assays as described in Materials and Methods. Expression of the GFP
2-fused Renilla luciferase (Rluc-GFP
2) served as a positive control. The data
represent the means 6 SDs of four independent readings from one representative result of four independent experiments (*P,0.01; paired t-test).
Expression levels of the indicated fusion proteins were determined by Western blot analysis of a portion of cell lysates using the respective
antibodies. (E) NPC-TW04 cells were transfected with 1 mg of plasmid for Flag-LMP1, its truncated form (DTM3–6), or empty vector, and then grown
for 24 h. Cell lysates were individually harvested for subcellular fractionation as described in Materials and Methods. Every fraction from fractions 1–9
and every other fraction from fractions 11–28 were analyzed by Western blotting with specific antibodies against LMP1, FGD4, b-actin, and CAV1.
doi:10.1371/journal.ppat.1002690.g005
Figure 6. Deletion of the transmembrane domains of LMP1 impairs its ability to co-localize with FGD4 and to promote cell motility.
(A) Co-localization of LMP1 with FGD4. NPC-TW02 cells grown on coverslips were transfected with 0.5 mg of expression plasmid for Flag-LMP1 or its
truncated or chimeric forms. Cells were fixed after a 24-h incubation and a following 6-h serum starvation, and then co-stained with primary anti-
FGD4 and anti-Flag antibodies and secondary FITC-conjugated (green) and TRITC-conjugated (red) antibodies, respectively. Nuclei were identifiedb y
DAPI staining (blue). Images were acquired using a ZEISS LSM510 confocal microscope as detailed in Materials and Methods. Scale bars, 10 mm. (B)
Induction of cell motility by LMP1. NPC-TW02 cells were transfected with the plasmid for Flag-LMP1 or its truncated or chimeric forms. After 24 h, the
cells were re-seeded for transwell migration assays as detailed in Materials and Methods. Images of migrating cells in each experiment were acquired
at 2006magnification. The number of migrating cells was counted and presented as the mean 6 SD of four independent experiments (*P,0.01,
**P,0.005; paired t-test). (C) The level of active Cdc42 under each condition was determined by GST-CBD pull-down assays of cell lysates prepared
from a portion of cells used in transwell migration assays, as described above. The amounts of GST-CBD were determined by Ponceau S staining.
doi:10.1371/journal.ppat.1002690.g006
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PLoS Pathogens | www.plospathogens.org 10 May 2012 | Volume 8 | Issue 5 | e1002690Figure 7. The action of the LMP1-FGD4-Cdc42 axis in NPC cells leads to actin rearrangement and increased cell motility. (A) NPC-
TW02 cells grown on coverslips were co-transfected with the indicated siRNA duplexes plus pEGFP-LMP1 or pEGFP vector, and then incubated for
48 h. Following a 6-h serum starvation, cells were fixed and stained with TRITC-conjugated phalloidin to examine actin filament (F-actin)
arrangement. Images were acquired using a ZEISS LSM510 confocal microscope. Scale bar, 20 mm. (B) NPC-TW02 cells were co-transfected with the
indicated siRNA duplexes and a Flag-LMP1 expression plasmid or empty vector. After 24 h, the cells were re-seeded for transwell migration assays as
detailed in Materials and Methods. Images of migrating cells in each experiment were acquired at 2006magnification. The number of migrating cells
was counted and presented as the mean 6 SD of four independent experiments (*P,0.001, **P,0.01; paired t-test). (C) The level of active Cdc42
under each condition was determined by GST-CBD pull-down assay of cell lysates prepared from a portion of cells used in transwell migration assays,
as described above. ND, not detectable. (D) NPC-TW02 cells were co-transfected with control or FGD4 siRNA plus a Flag-LMP1 expression plasmid or
empty vector, with and without co-transfection of an expression plasmid for Flag-Cdc42DN (DN) or Flag-Cdc42CA (CA). At 24 h post-transfection, the
cells were re-seeded for transwell migration assays. Images of migrating cells in each experiment were acquired at 2006magnification. The number
of migrating cells was counted and presented as the mean 6 SD of three independent experiments (*P,0.05, **P,0.01; paired t-test). (E) The level of
active Cdc42 under each condition was determined by GST-CBD pull-down assay of cell lysates prepared from a portion of cells used in transwell
migration assays, as described above.
doi:10.1371/journal.ppat.1002690.g007
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motility, we next performed transwell migration assays using NPC
cells co-expressing Flag-LMP1 and siRNA specific for FGD4 or
Cdc42. The data revealed that, compared to vector-transfected
cells, expression of LMP1 in control siRNA (siCtrl)-treated cells
increased cell motility (Figure 7B, P=0.0001). This LMP1-
induced cell motility was reduced by approximately 50% by
knockdown of either FGD4 (P=0.008) or Cdc42 (P=0.005;
Figure 7B). This reduced cell motility was associated with a
decreased level of LMP1 activation of Cdc42; knockdown of
FGD4 decreased the fold-increase in active Cdc42 from 4.7 to 0.9,
and knockdown of Cdc42 decreased active Cdc42 to undetectable
levels (Figure 7C). Despite its specificity toward Cdc42, FGD4 has
also been shown to indirectly promote Rac1 activation [44]. To
clarify whether Rac1 activation was involved in LMP1-induced
cell motility, we assessed the level of active Rac1 using NPC cells
prepared from similar experiments as described above. The results
revealed that neither knockdown of FGD4 nor reconstitution of
FGD4 can affect the activation of Rac1 in NPC cells (Figure S5A
and S5B). In addition, knockdown of Cdc42 had no effect on the
activation of Rac1 or RhoA (Figure S5C). Furthermore, neither
knockdown of Rac1 nor knockdown of RhoA can affect the
LMP1-induced cell motility (Figure S5D and S5E). Taken
together, these data conclusively demonstrated that Rac1 and
RhoA are not involved in LMP1-induced cell migration of NPC
cells.
To buttress the requirement of Cdc42 activity for the LMP1-
induced cell motility, we conducted the transwell assays similar
to those used in Figure 7B, except we co-expressed Flag-LMP1
with Flag-Cdc42DN (a dominant negative mutant) in control
siRNA-treated cells to block Cdc42 activity, or co-expressed
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bypass the effect of FGD4 depletion. As shown in Figure 7D,
co-expression of LMP1 with Cdc42DN reduced LMP1-induced
cell motility by approximately 50% (P=0.02; paired t-test), a
reduction reminiscent of the effect of FGD4 depletion
(Figure 7B). Conversely, co-expression of LMP1 with Cdc42CA
partially reversed the reduction in cell motility caused by FGD4
depletion (Figure 7D, P=0.004), revealing that active Cdc42 was
responsible for mediating the cell migration triggered by the
LMP1-FGD4 axis.
Both LMP1 and FGD4 are expressed in NPC tissues
To explore the physiological relevance of LMP1 and FGD4 in
NPC, we assessed LMP1 and FGD4 expression in NPC
specimens. We first performed quantitative RT-PCR analyses
using mRNAs isolated from specimens from 13 NPC patients and
14 controls. As shown in Figure 8A, LMP1 mRNA expression was
exclusively detected in NPC specimens. Moreover, FGD4 mRNA
was expressed at a higher level in NPC specimens than in controls
(0.42260.173 vs. 0.13160.135; P=0.0005; two-tailed Mann
Whitney test); however, no correlation was observed between the
levels of FGD4 and LMP1 mRNA (P=1; Spearman test). To
detect FGD4 and LMP1 proteins in NPC specimens, we next
conducted immunohistochemical staining for FGD4 and LMP1
on consecutive NPC tissue sections from 48 NPC cases. Among
them, both FGD4 and LMP1 were detectable in 29 cases and no
correlation was shown between the levels of FGD4 and LMP1
(P=0.85; Spearman test). Despite this, it was notable that LMP1
and FGD4 exhibited similar staining patterns, prominently at the
cell membrane, as shown in three representative cases (Figure 8B).
These data provide a potential physiological relevance for the
LMP1-FGD4 interaction in NPC tissues.
Collectively,ourdata reveal that LMP1 induces Cdc42activation
by directly binding to FGD4, promoting actin rearrangement and,
ultimately, cell migration.
Discussion
Although Puls et al. have previously linked Cdc42 activation to
LMP1-induced actin rearrangement in fibroblasts [17], the
molecular basis of Cdc42 activation by LMP1 and its role in
EBV-associated malignancy remained to be elucidated. Here, we
demonstrated that LMP1 induces Cdc42 activation in NPC cells
via a direct interaction with the Cdc42-specific GEF, FGD4,
leading to actin remodeling and increased cell motility. We further
verified the expression of LMP1 and FGD4 in NPC specimens,
not only providing support for the physiological relevance of this
mechanism but also linking FGD4 to tumorigenesis for the first
time.
Pathogenic microbes, including viruses, commonly hijack the
host cell processes, such as cytoskeleton reorganization, to benefit
their own survival in aspects of attachment, entry into cells,
movement within and between cells, as well as vacuole formation
and remodeling [45,46]. In addition to LMP1, several viral
proteins have been documented to affect the function of Rho
protein, which is highly involved in the regulation of cytoskeleton
organization. For instance, the E6 oncoprotein of high-risk human
papilloma virus type 16 interacts with a binding partner of a GEF
(ARHGEF16) to coordinate Cdc42 activation [47], and the Nef
protein of human immunodeficiency virus type 1 recruits the GEF
Vav1 into plasma membrane microdomains, where it associates
with and activates Cdc42/PAK2 (p21-activated kinase 2) [48]. To
our knowledge, our evidence that LMP1 elicits Cdc42 activation
via direct binding to a Cdc42-specific GEF is the first such
demonstration for a viral oncoprotein. It has been proposed that
FGD4 is targeted to a preexisting specific actin structure through
its FAB domain [35]. LMP1 interaction with FGD4 likely
promotes recruitment of FGD4 to the sites where LMP1 is
present (Figure 5E and 6A) and thereby elicits Cdc42 activation in
the vicinity of the actin structure associated with FGD4 (Figures 2D
and S2). This process ultimately results in spatial reorganization of
the actin cytoskeleton and regulates cell morphogenesis and cell
motility [35,49], in line with our observation that LMP1 induces
the formation of filopodia at the cell surface (Figures 2D and 7A)
and promotes cell migration via FGD4/Cdc42 (Figure 7B–7E).
In this study, we demonstrated that LMP1 directly interacts
with FGD4 (Figure 5C and 5D) and enhances FGD4 activity
toward Cdc42 (Figure 4F). The LMP1-FGD4 interaction requires
the transmembrane domains 3 and 4 of LMP1 and the PH1-to-
PH2 domains (phosphoinositide-binding domains) of FGD4
(Figures 4E, 4F, 5A, and 5B), indicating that the membrane/lipid
association of both proteins may allow or enhance their
interaction. We have previously identified that upon synthesis in
the endoplasmic reticulum (ER), LMP1, through its transmem-
brane domains 3–6, interacts with PRA1 (the prenylated Rab
acceptor 1) for transport from the ER to the Golgi apparatus [50],
an intracellular compartment where LMP1 primarily induces
signaling pathways [50,51]. Deletion of the LMP1 transmembrane
domains (in particular 3–6) or knockdown of PRA1 leads to LMP1
retention in the pre-Golgi compartment (Figures 2D, 5E, 6A, and
S2B; [50]) concomitant with a reduction of Cdc42 activation
(Figures 2B, 2C, and 6C; data not shown), implying that the
proper localization of LMP1 is needed for its full activation of
Cdc42. These data elicit an argument that the impaired FGD4
interaction of the truncated LMP1 (DTM3/4 and DTM3–6)
actually arises from the impaired trafficking process instead of
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that LMP1 interacts with FGD4 via the transmembrane domains
3 and 4, and subsequently recruits and/or enhances FGD4
association with the membrane during the Golgi-directed traffick-
ing of LMP1 (Figure 8C). This model is supported by several lines
of data as the following. First, expression of LMP1 but not its
truncated form (in particular DTM3–6) leads to FGD4 redistri-
bution toward the LMP1-containing fractions as demonstrated by
subcellular fractionation (Figure 5E) and immunofluorescence
staining (Figure 6A). These data suggest that LMP1 interaction
with FGD4 indeed occurs prior to LMP1 localization to specific
compartments. Second, the short N-terminus and the transmem-
brane domains 1 and 2 of LMP1 have been shown to be required
for targeting of LMP1 to the lipid raft [52,53]. Deletion of these
domains (denote DNT and DTM1/2) also impedes the Golgi-
directed trafficking of LMP1 (data not shown; Figures 2D and 6A)
but does not abolish LMP1 interaction with FGD4 (Figure 5A and
5B), revealing that this interaction is not restricted at certain
compartments but rather relies on the transmembrane domains 3
and 4 of LMP1. Agreeably, the CD40CT chimera fails to interact
with FGD4 (Figures 4F, 5A, and 5B) despite its intact membrane
localization (Figures 2D and 6A).
Figure 8. Expressions of LMP1 and FGD4 in NPC tissues. (A) Elevated FGD4 mRNA levels in NPC specimens compared with normal
nasopharyngeal tissues. mRNA was isolated from specimens of 13 NPC patients (NPC) and 14 control individuals with nasosinusitis (NPN). Each mRNA
sample was then reverse transcribed and analyzed by quantitative RT-PCR using specific primer sets. The expression levels of FGD4 or LMP1 in each
specimen were determined by normalizing the reading of FGD4 or LMP1 to that of COL4A6 (Collagen, type IV, alpha), an internal control that showed
a consistent expression level among specimens. The data were analyzed by Box-plot analyses. The box indicates the 25th and 75th percentiles of the
data range; the middle line indicates the median (*P=0.0005; two-tailed Mann Whitney test). (B) Immunohistochemical staining for LMP1 and FGD4
in formalin-fixed, paraffin-embedded consecutive NPC tissue sections. Predominant expression of LMP1 and FGD4 was detected at the cell
membrane. The images shown are representative from three cases and were acquired at 4006magnification. (C) Model for the action of the LMP1-
FGD4-Cdc42 axis in NPC cells. The viral oncoprotein LMP1 interacts with FGD4, a Cdc42 GEF, mainly through the transmembrane domains 3 and 4
(TM3/4) of LMP1 and the PH1-to-PH2 domains (PH1-2) of FGD4. During the intracellular trafficking of LMP1 to the lipid-rich compartments (the Golgi
apparatus and the plasma membrane), LMP1 interaction with FGD4 may promote membrane association, oligomerization, and/or conformation
change of FGD4, leading to an enhanced FGD4 activity toward Cdc42. The LMP1-involved membrane association of FGD4 may also increase the
chance for FGD4 to recruit Cdc42 (via the FGD4 DH domain) that is targeted to the membrane by independent mechanisms, thereby inducing Cdc42
activation. Once activated, active Cdc42 subsequently binds downstream effectors that are involved in regulating the arrangement of actin filament,
ultimately contributing to increased cell motility of NPC cells.
doi:10.1371/journal.ppat.1002690.g008
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protein interaction [54–56], it is assumed that FGD4 activation is
potentiated by interaction with LMP1 or self-oligomerization
(Figure S4C). Further localization of LMP1 and FGD4 to lipid-
rich compartments (the Golgi apparatus and the plasma mem-
brane) likely strengthens the LMP1-FGD4 interaction and the
membrane association of FGD4, leading to an enhanced FGD4
activity toward Cdc42 (the model in Figure 8C). Conceivably, the
lipid in the membrane may enhance stimulation of FGD4
activities. In line with this, deletion of the PH1-to-PH2 domains
of FGD4 substantially impairs its activation of Cdc42 (Figure 4C),
indicating that membrane/lipid association is involved in the
regulation of FGD4 activity. As the truncated LMP1 (DTM3/4
and DTM3–6) still retains ,30% activation of Cdc42, we
speculate that the targeting of LMP1 to the lipid raft (via the N-
terminus and the transmembrane domains 1 and 2) may indirectly
assist FGD4 to associate with the lipid/membrane. Further
investigation will be needed to clarify the mechanisms in greater
details. Importantly, LMP1-induced Cdc42 activation can be
blunted by knockdown of FGD4 (Figure 3) or overexpression of
functionally impaired forms of FGD4 (Figure 4D), indicating that
LMP1 acts upstream of FGD4 rather than in parallel with it to
induce Cdc42 activation. We propose that the functionally
impaired forms of FGD4 (DDH and PH1-2) inhibit LMP1-
induced Cdc42 activation by competitively impeding the interac-
tion between LMP1 and full-length FGD4 (Table S1). Intriguingly,
the FAB-DH form of FGD4, which interacts poorly with LMP1,
could still inhibit LMP1-induced Cdc42 activation, probably by
competing with full-length FGD4 for access to Cdc42. Apart from
this, phosphatidylinositol 3-kinase (PI3K) has been linked to the
translocation of FGD4 during infection of the enteric parasite
Cryptosporidium parvum [57]. In this case, C. parvum infection induces
recruitment of FGD4 to the host cell-parasite interface; this
process, which results in Cdc42 activation, is dependent on PI3K
and is required for C. parvum-induced actin remodeling and cellular
invasion [57]. Although it has been demonstrated that LMP1 is
able to act through its C-terminus to activate PI3K [58], our study
found that this region is dispensable for LMP1 activation of Cdc42
(Figure 2B). Moreover, treatment of LMP1-expressing cells with
the PI3K inhibitors, wortmannin and LY294002, did not block the
LMP1-induced Cdc42 activation (data not shown), indicating that
the LMP1-associated functional regulation of FGD4 involves the
LMP1-FGD4 interaction instead of PI3K activity.
We noted that LMP1, together with FGD4, is expressed
heterogeneously at the plasma membrane as well as the Golgi
apparatus (Figure 6A) and induces Cdc42 activation at these sites
(Figure S2A). It has been suggested that restricted localization of
active Cdc42 is important for its distinct functions [59], suggesting
the possibility that LMP1 induction of Cdc42 activation at the
plasma membrane and the Golgi apparatus serves distinct
purposes. Given that Cdc42 also controls the intracellular protein
trafficking, including the Golgi-to-ER retrograde transport [60,61]
and protein exit from the trans-Golgi network [19,62], it is
conceivable that the LMP1-FGD4-Cdc42 cascade may have a
regulatory role in intracellular protein transport apart from cell
migration. We speculate that LMP1-induced Cdc42 activation
may attenuate Golgi-to-ER retrograde protein transport [60],
promoting LMP1 retention at the Golgi apparatus and sustaining
LMP1-mediated signaling. Further investigation will be needed to
dissect the interplays between LMP1 and FGD4 within distinct
compartments and elucidate how their functions are coordinated
to affect cellular processes.
Although FGD4 has been implicated in neural development
[29,63,64], we here delineate a potential role for FGD4 in NPC
progression that is associated with LMP1. We verified the
expression of LMP1 and FGD4 in NPC tissues at both mRNA
and protein levels using the quantitative RT-PCR and immuno-
histochemistry, respectively (Figure 8A and 8B). Intriguingly,
FGD4 mRNA expression appears to be elevated in cancerous
tissues compared to the normal controls (Figure 8A), although the
underlying mechanism remains to be identified. In any case, it is
conceivable that higher levels of FGD4 in NPC tissues lead to an
increase in FGD4 function. In addition, it was recently shown that
FGD1, which is functionally related to FGD4, is up-regulated in
human prostate and breast cancer, and regulates cancer cell
invasion by modulating Cdc42 activation in a cell model [65].
Accordingly, our findings highlight the importance of elucidating
the mechanism by which FGD4 and its related proteins are
dysregulated in tumor development.
Materials and Methods
Ethics statement
This research followed the tenets of the Declaration of Helsinki
and all subjects signed an informed consent approved by
Institutional Review Board of Chang Gung Memorial Hospital
before their participation in this study and for the use of tissue
samples collected before treatment.
Cell culture
NPC-TW01, -TW02, -TW04 and -TW06 cell lines, which had
been established using NPC biopsy specimens collected from four
NPC patients, respectively [66,67], were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) at 37uC in a humidified 5% CO2 environ-
ment. The inducible LMP1-expressing 293 cell line (293 Tet-On),
generated previously [50], was grown on 1% collagen-coated
dishes and maintained in DMEM supplemented with 10% FBS,
100 mg/ml G418, and 50 mg/ml hygromycin. The human
embryonic kidney cell line HEK293, obtained from American
Type Culture Collection (ATCC; CRL 1573), was grown on 1%
collagen-coated dishes and cultured in DMEM containing 10%
equine serum. The nasopharyngeal epithelium cell line (NP69) and
a stable LMP1-expressing NP69 cell line (NP69-LMP1) were
generous gifts from Dr. Sai-Wah Tsao (University of Hong Kong,
China). The growth medium used for NP69 and NP69-LMP1 cells
has been previously described in detail [68]. Unless specified, all
the reagents were purchased from Invitrogen (Carlsbad, CA,
USA).
Clinical specimens
Freshly frozen biopsied tissues from 13 NPC patients and 14
control individuals with nasosinusitis, and slide-mounted consec-
utive NPC tissue sections from 48 NPC patients were collected at
Chang Gung Memorial Hospital (Lin-Kou, Taiwan). Clinical data
for the NPC patients are presented in Table S2.
Antibodies
The anti-LMP1 monoclonal antibody (S12) was affinity purified
from a hybridoma. Mouse anti-Flag (M2) and anti-HA (12CA5)
antibodies were purchased from Sigma-Aldrich (St. Louis, MO,
USA); a mouse anti-Myc tag (9E10) antibody was purchased from
Cell Signaling Technology (Danvers, MA, USA); mouse anti-
human Cdc42 and anti-Rac1 antibodies were purchased from BD
Transduction Laboratories (BD Biosciences, San Jose, CA, USA);
a mouse anti-human RhoA antibody was purchased from Santa
Cruz Biotechnologies, Inc. (Santa Cruz, CA, USA). Rabbit
antibodies against human DOCK9, intersectin-1, FGD3, and
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anti-human FGD1 antibody was purchased from GeneTex
(Irvine, CA, USA); rabbit anti-human FGD4 antibody was
purchased from both Novus Biologicals (Littleton, CO, USA)
and GeneTex (Irvine, CA, USA). Fluorescein isothiocyanate
(FITC)-, tetramethylrhodamine isothiocyanate (TRITC)-, and
horseradish peroxidase (HRP)-conjugated secondary antibodies
were purchased from BD Transduction Laboratories.
Plasmid construction
N-terminally Flag-tagged LMP1 as well as its truncated
derivatives were generated by ligation of PCR-amplified DNA
fragments to HindIII/BamHI-treated pCMV2-Flag (Kodak) as
described previously [50]. GFP-tagged LMP1 was generated by
ligation of DNA fragments to HindIII/BamHI-treated pEGFP-C3
(BD Biosciences). Full-length and truncated FGD4 constructs were
generated by PCR using human FGD4 cDNA as a template; the
resulting DNA fragments were subsequently inserted into
pCMV2-Flag at the EcoR1/XbaI sites or into pCMV-Myc (BD
Biosciences) at the KpnI/XbaI sites. Glutathione S-transferase
(GST)-tagged full-length FGD4 construct was created by ligating
the respective PCR-amplified DNA fragments into EcoRI/XhoI-
treated pGEX 4T.1 (BD Biosciences). Plasmids encoding the GST
fusion proteins, GST-CBD (containing the active Cdc42-binding
domain of Wiskott-Aldrich syndromewith protein, WASP; aa 201–
321), GST-PBD (containing the active Rac1-binding domain of
PAK1; aa 70–132), and GST-RBD (containing the active RhoA-
binding domain of Rhotekin; aa 7–113) were gifts from Dr.
Jacques Bertoglio (INSERM U461, Faculte ´ de Pharmacie-Paris
Sud, Chatenay-Malabry, France). pEGFP-CBD was generated by
subcloning the DNA fragments encoding the CBD of WASP into
pEGFP-C3. Flag-tagged, constitutively active (CA) and dominant-
negative (DN) versions of Cdc42, Cdc42L61 and Cdc42N17,
respectively, were generated by site-directed mutagenesis using
primers bearing the desired sequence changes. The DNA
fragments were subsequently inserted into pCMV2-Flag at
EcoRI/BamHI sites. For BRET
2 assays, N-terminally Rluc-tagged
LMP1 and GFP
2-tagged FGD4 were generated by ligation of
PCR-amplified DNA fragments into KpnI/BamHI-treated
pRluc(h)-C2 and KpnI/XbaI-treated pGFP
2-C1 vectors (PerkinEl-
mer Life and Analytical Sciences, MA, USA), respectively. Primer
sequences used for cloning are provided in Table S3.
Cell transfection and RNA interference
Unless specified, plasmid transfections were carried out using
Lipofectamine (Invitrogen), according to the manufacturer’s
instructions. Cells were incubated for 24 h prior to further
treatments. For RNA interference, cells were co-transfected with
25 nM siRNAs as a set of four duplexes (SMARTpool) directed
against a specific gene, together with plasmids indicated elsewhere,
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. Cells transfected with non-targeting duplexes
(siCtrl) were used as a negative control. Cells were incubated for
48 h before further treatments, and the efficiency of gene silencing
was estimated by quantitative RT-PCR and Western blotting. All
siRNAs were purchased from Dharmacon (CO, USA) except
Rac1 siRNAs, which were purchased from Invitrogen.
Quantitative RT-PCR
Total RNA was purified using TRIzol (Invitrogen) and 1 mgo f
each sample was reverse transcribed using ImProm-II and
Oligo(dT)15 primers (Promega). The resulting cDNAs were
analyzed using the FastStart DNA Master SYBR Green I reagent
(Roche, Germany) on a LightCycler (Roche), according to the
manufacturer’s instructions. The reactions were incubated at 95uC
for 10 min, followed by 45 cycles of 95uC for 10 s, 60uC for 5 s
and 72uC for 10 s. Primer sequences used in RT-PCR experi-
ments are presented in Table S4. The levels of individual target
mRNAs were normalized to the level of glyceraldehyde-3-
phosphate dehydrogenase (GADPH) mRNA in each sample.
Purification of GST-fusion proteins
pGEX construct-transformed Escherichia. coli (strain BL21) were
grown to mid-exponential phase, induced for 4 h with 0.5 mM
isopropylthiogalactoside and lysed by sonicating in PBST buffer
(16phosphate-buffered saline [PBS] with 2 mM EDTA, 0.1% b-
mercaptoethanol, 0.2 mM phenylmethylsulfonyl fluoride [PMSF],
and 5 mM benzamidine). The GST fusion proteins were purified
from bacterial lysates by incubation with glutathione-coupled
Sepharose beads (Amersham Biosciences).
Precipitation of active Cdc42, Rac1, and RhoA
The cellular level of the GTP-bound form of Cdc42 was
determined using the GST-CBD pull-down assays. Briefly, at
given incubation time after transfection, cells were cultured in
serum-free media for an additional 6 h and lysed in Nonidet P-40
(NP-40) lysis buffer (1% NP-40, 20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM Na3VO4, 5 mM EDTA pH 8.0, 10%
glycerol, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM PMSF).
After centrifugation, the resulting lysates (1 mg protein) were
incubated with 20 mg of immobilized GST-CBD proteins at 4uC
for 1 h. CBD-bound proteins were centrifuged, washed three
times in NP-40 lysis buffer, boiled in sodium dodecyl sulfate (SDS)
sample buffer and analyzed by Western blotting, as described
below, using a Cdc42-specific antibody. GST-PBD and GST-
RBD were used for precipitation of active forms of Rac1 and
RhoA, respectively, following a similar procedure.
In vitro transcription/translation and in vitro affinity
chromatography assays
Full-length LMP1 cDNA was constructed and cloned into
pcDNA3.1 for in vitro transcription/translation. [
35S]methionine-
labeled proteins were generated using the TNT Coupled
Reticulocyte Lysate System (Promega, Madison, WI, USA),
following the manufacturer’s recommendation. Briefly, a reaction
mixture (total volume, 100 ml) containing 50 ml of TNT Rabbit
Reticulocyte Lysate, 4 ml of TNT Reaction Buffer, 2 ml of TNT
T7 RNA Polymerase, 2 ml of Amino Acid Mixture Minus
Methionine (1 mM), 2 ml of RNasin Ribonuclease Inhibitor
(Promega), 2 mg of pcDNA3.1-LMP1, 4 mlo f[
35S]methionine
(10 mCi/ml; Izotop, Hungary), 4 ml of Canine Pancreatic
Microsomal Membrances (Promega), and 30 ml of nuclease-free
water was incubated at 30uC for 90 min. Equal amounts of the in
vitro-translated, [
35S]methionine-labeled LMP1 protein were incu-
bated with 20 mg of GST or GST-FGD4 immobilized on
glutathione-Sepharose beads, rotated overnight at 4uC, and then
washed five times with NP-40 lysis buffer. The bound LMP1
proteins were resolved by SDS-PAGE on a 10% gel followed by
autoradiography.
Co-immunoprecipitation assays
Cells expressing Flag-tagged and/or Myc-tagged proteins were
extracted in 1% NP-40 lysis buffer as described above and
fractionated by centrifugation (10,000 g, 15 min at 4uC) to obtain
cell lysates. For co-immunoprecipitation, cell lysates (500 mg
protein) from NPC cells expressing Flag- or Myc-tagged proteins
were incubated with 40 ml of a 50% (w/v) slurry of anti-Flag M2
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anti-Myc affinity matrix (Sigma-Aldrich), rotated overnight at 4uC,
and then washed five times with NP-40 lysis buffers. For co-
immunoprecipitation of endogenous FGD4 and LMP1, cell lysates
(1 mg protein) from NPC cells expressing LMP1 were incubated
with 2 mg of anti-FGD4 IgG or control IgG together with 20 mlo f
a 50% (w/v) slurry of protein G (Amersham Biosciences), and
further processed using procedures similar to those above. The
resulting protein products were eluted with SDS sample buffer and
analyzed by Western blotting using appropriate primary and
secondary antibodies.
Western blot analysis
Cells were lysed in 1% NP-40 lysis buffer as described above.
Protein concentrations were determined using the Protein Assay
Reagent (Bio-Rad, CA, USA), and equal amounts of proteins (30–
50 mg/lane) were resolved by SDS-polyacrylamide gel electropho-
resis (SDS-PAGE) on 7.5%–12% polyacrylamide gels. The
proteins were then electro-transferred onto nitrocellulose (NC)
membranes (Amersham Biosciences). After blocking with 5% non-
fat powdered milk in TBS, membranes were incubated with the
respective primary antibodies overnight at 4uC. Membranes were
then incubated with the appropriate HRP-conjugated secondary
antibody for 1 h at room temperature. Protein bands were
detected using enhanced chemiluminescence reagents (Pierce
ECL, Thermo Scientific) and Fuji SuperRx film.
BRET
2 assay
NPC-TW01 cells grown on a 10 cm-dish were transfected with
plasmids encoding donor Renilla luciferase (Rluc)-tagged LMP1
(1 mg) and acceptor GFP
2-tagged FGD4 (3 mg). Cells were
detached at 24 h after transfection and washed with Dulbecco’s
Phosphate Buffered Saline (D-PBS; Invitrogen) and then resus-
pended in D-PBS to a final density of approximately 2610
6 cells/
ml. Approximately 1610
5 cells/well were distributed in a 96-well
white polystyrene microplate (Conig, NY, USA). The DeepBlueC
coelenterazine substrate (PerkinElmer Life and Analytical Scienc-
es) was added to a final concentration of 5 mM, and biolumines-
cence emission was monitored immediately using a Fluoroskan
Ascent FL microplate fluorometer (Thermo Electron Corporation,
MA, USA), which allows the sequential integration of signals
detected in 410-nm and 515-nm windows. The BRET
2 ratio is
calculated as the following ratio: (emission of transfected cells at
515 nm – emission of non-transfected cells at 515 nm)/(emission
of transfected cells at 410 nm – emission of non-transfected cells at
410 nm). The expression level of each fusion protein was analyzed
by Western blotting with appropriate antibodies.
Subcellular fractionation
NPC-TW04 cells grown on a 10-cm dish were transfected with
1 mg of pFlag-LMP1, pFlag-LMP1DTM3–6, or pFlag-CMV2
vector and incubated for 24 h. Cells were then homogenized and
centrifuged, and the resulting supernatant was layered onto a
continuous sucrose gradient (10%–45% sucrose) and centrifuged
for 1 h at 55,000 rpm. using an SW55 rotor (Beckman, Fullerton,
CA, USA). The fractions were collected manually from the top of
the gradient and 30 ml of every other fraction was subjected to
Western blot analysis. Details of this assay have been described
previously [50,69].
Immunofluorescence microscopy
Cells grown on poly-L-lysine-coated coverslides were fixed with
4% formaldehyde, and permeabilized and blocked with 0.1%
saponin containing 1% BSA for 20 min at room temperature. For
co-staining of Flag-LMP1 and FGD4, cells were incubated with
anti-Flag antibody (M2; 1:200 dilution) and anti-FGD4 antibody
(GeneTex; 1:50 dilution) for 2 h at room temperature, followed by
incubation with the respective fluorophore-conjugated secondary
antibody for 45 min. For actin filament staining, cells were
incubated in TRITC-conjugated phalloidin (50 mg/ml; Sigma-
Aldrich) for 1 h after fixation. Nuclei were stained with 49,6-
diamidino-2-phenylindole (DAPI; Sigma-Aldrich). All coverslides
were mounted with the Vectashield reagent (Vector Laboratories
Inc., CA, USA) and visualized by confocal microscopy using a
ZEISS LSM510 META laser-scanning confocal microscope (Carl
Zeiss, Germany) with a 6361.32 NA oil-immersion objective.
Immunohistochemistry
For detection of LMP1 and FGD4, consecutive slide-mounted
NPC sections were first treated with proteinase K at room
temperature for 15 min. Endogenous peroxidase activity was
inhibited by incubating with 3% H2O2 (DAKO). Nonspecific
binding was blocked with Antibody Diluent and Background
Reducing Component (DAKO). Sections were then incubated
with anti-FGD4 (GeneTex; 1:50 dilution) and anti-LMP1 (S12,
1:15 dilution) antibodies at room temperature for 1 h. After a
washing step, a HRP-conjugated secondary antibody was added
and sections were incubated at room temperature for 20 min.
Tissue sections were then treated with DAB reagent (DAKO);
3,39-diaminobenzidine tetrahydrochloride was used as a chromo-
gen. All images were acquired on an Olympus BX51 microscope
(Olympus, Japan). Expression of LMP1 and FGD4 was evaluated
according to the simplified H score system [70], which is based on
the percentage of cell staining: 3 ($90%), 2 (50%–89%), 1 (10%–
49%), or 0 (0%–9%), and the intensity of cell staining: 3 (high), 2
(moderate), 1 (low), or 0 (no cell staining). The two scores were
multiplied by each other and then divided by three to get the final
score.
Transwell migration assay
The motility of NPC-TW02 cells was evaluated by transwell
migration assays using a chemotaxis chamber (Corning, NY,
USA). Using calcium phosphate precipitation, NPC-TW02 cells
were transfected with 1 mg of plasmid for Flag-LMP1, its
transmembrane domain-truncated forms, CD40CT chimera, or
empty vector. For knockdown experiments, NPC-TW02 cells were
co-transfected with siRNAs (37.5 nM) directed against FGD4
(siFGD4), Cdc42 (siCdc42) or non-targeting duplexes (siCtrl), plus
1 mg of pFlag-LMP1 or pCMV-Flag vector. In a subset of assays,
cells were co-transfected with pFlag-LMP1 (0.75 mg) plus pFlag-
Cdc42DN or pFlag-Cdc42CA (1.5 mg each). The oligonucleotides
were mixed thoroughly in 250 ml of solution A (136.7 mM NaCl,
19.2 mM HEPES, pH 6.95), 2.5 ml of solution B (57.6 mM
Na2HPO4), and 12.5 ml of solution C (2.5 M CaCl2). After 30-min
incubation at room temperature, the mixtures were added to cells
and incubated for 6 h at 37uC. Twenty-four hours after
transfection, cells were trypsinized and washed twice with
serum-free DMEM, and then resuspended in 100 ml of serum-
free DMEM and seeded into the insert chamber (3610
5 cells).
After a 20-h incubation, cells that had migrated to the opposite
side of the insert (immersed in DMEM supplemented with 10%
FBS) in the lower well were fixed and stained with crystal violet
(1% crystal violet and 5% formaldehyde in 70% ethanol) for
30 min, followed by washing twice with double-distilled H2O
(ddH2O) to remove the background staining. The number of
migrating cells was counted in images acquired at 2006
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J software.
Statistical analyses
Quantitative data were presented as means 6 SDs for five
independent experiments. Significance between groups was
calculated using two-tailed paired t-tests. For clinical specimens,
significance between groups was calculated using two-tailed
Mann-Whitney tests. Correlation between groups was analyzed
using two-tailed Spearman tests. A P-value,0.05 was considered
statistically significant.
Accession numbers
The Entrez Gene ID numbers for genes or proteins described in
this study are as follows: 5176215 (LMP1), 121512 (FGD4), 998
(Cdc42), 5879 (Rac1), 387 (RhoA), 60 (b-actin), 2245 (FGD1),
89846 (FGD3), 6453 (Intersectin-1), 23348 (DOCK9), 857
(CAV1), 7124 (TNF), 3552 (IL-1a), 958 (CD40).
Supporting Information
Figure S1 No apparent effect of TNF-a and IL-1a on
Cdc42 activation in NPC cells. (A) Neither TNF-a nor IL-1a
can induce Cdc42 activation. NPC-TW01 cells cultured for 24 h
after seeding were treated with recombinant TNF-a (50 or
100 ng/ml) or with IL-1a (10 ng/ml) for 30 min under a serum-
free condition. Cells without cytokine treatment were used as a
control. Each cell lysate was then harvested for the GST-CBD
pull-down assays to determine the level of active Cdc42. A reduced
protein level of IkBa indicates the activation of NF-kB signaling
under the indicated treatment. (B) No apparent effect of TNF-a
and IL-1a on actin organization. NPC-TW04 cells that had been
grown on poly-L-lysine-coated coverslips overnight were treated
with TNF-a (100 ng/ml) or with IL-1a (10 ng/ml) for 30 min
under a serum starvation condition. Then cells were fixed and
permeabilized, followed by subsequent staining with primary anti-
p65 and FITC-conjugated secondary antibodies. Cells were co-
stained with TRITC-conjugated phalloidin to reveal the actin
filaments. Nuclei were identified by DAPI staining. Translocation
of p65 from the cytoplasm to the nuclei evidenced the activation of
NF-kB signaling. Images were acquired using a ZEISS LSM510
confocal microscope. Scale bars, 20 mm.
(PDF)
Figure S2 LMP1 appears to induce Cdc42 activation at
LMP1-resident sites. (A) Spatial distribution of active Cdc42
upon LMP1 expression. 293 Tet-On cells that had been grown on
poly-L-lysine-coated coverslips overnight were transfected with
1 mg of plasmid encoding an indicator for active Cdc42, EGFP-
CBD, and incubated for 24 h with or without Dox (5 mg/ml)
induction of LMP1 expression. Following a 6-h serum starvation,
cells were fixed with 3.7% formaldehyde and subsequently stained
with primary anti-LMP1 (S12) and TRITC-conjugated secondary
antibodies. Nuclei were identified by DAPI staining (blue). Images
were acquired using a ZEISS LSM510 confocal microscope. Scale
bars, 15–17 mm. The insets were acquired at higher magnification
(scale bars, 2–5 mm). (B) Co-localization of a portion of Cdc42
with LMP1. NPC-TW04 cells grown on coverslips overnight were
transfected with 0.5 mg of plasmid for EGFP-LMP1 or its DTM3–
6 truncated form and then incubated for 24 h. Following a 6-h
serum starvation, cells were fixed and subsequently stained with a
primary anti-Cdc42 antibody (P1, Santa Cruz; 1:50 dilution) and a
TRITC-conjugated secondary antibody. Nuclei were identified by
DAPI staining (blue). Images were acquired using a ZEISS
LSM510 confocal microscope. Scale bars, 20 mm. The insets
demonstrated co-localization of a portion of Cdc42 with EGFP-
LMP1 (yellow spots) rather than with the DTM3–6 form.
(PDF)
Figure S3 Knockdown of FGD4 in NPC cells and
sequence comparison of FGD4 between species. (A)
Knockdown efficiency of the targeted GEFs in NPC cells
expressing LMP1 or transfected with empty vector (control). Total
RNA isolated from cells of each treatment group was reverse
transcribed and analyzed by quantitative RT-PCR using specific
primer sets. The knockdown efficiency for each targeted GEF in
each treatment is presented as a ratio of the mRNA level of each
GEF in the knockdown cells divided by that in the respective
control. (B) Sequence comparison of human, rat, and mouse
FGD4. Shaded regions represent the conserved functional
domains of FGD4. Asterisks (*) indicate identical amino-acid
residues.
(PDF)
Figure S4 Functional characterization of FGD4. (A) NPC-
TW01 cells grown on coverslips overnight were transfected with
0.5 mg of plasmid for Myc-FGD4 or its truncated forms and then
incubated for 24 h. Following a 6-h serum starvation, cells were
fixed and subsequently stained with a primary anti-Myc antibody
(9E10) and a FITC-conjugated secondary antibody. Then the cells
were co-stained with TRITC-conjugated phalloidin to indicate the
actin filaments. Images were acquired using a ZEISS LSM510
confocal microscope. Scale bars, 20 mm. (B) FGD4 associates with
Cdc42 mainly through the DH domain. NPC-TW01 cells were
co-transfected with 1 mg of expression plasmid for Flag-tagged
Cdc42 and 1 mg of expression plasmid for Myc-tagged full-length
or truncated FGD4. At 24 h post-transfection, the cells were lysed
and the resulting cell lysates were analyzed by co-immunoprecip-
itation using an anti-Flag affinity matrix. The precipitated proteins
as well as unprecipitated lysates (input) were analyzed by Western
blotting with anti-Flag and anti-Myc antibodies. (C) Self-
association of FGD4. NPC-TW01 cells were co-transfected with
1 mg of expression plasmid for Flag-FGD4 and 1 mg of expression
plasmid for Myc-FGD4 or its truncated forms. At 24 h post-
transfection, the cells were lysed and the resulting cell lysates were
subjected to co-immunoprecipitation assays using an anti-Flag
affinity matrix, as described above.
(PDF)
Figure S5 Rac1 and RhoA are not involved in the NPC
cell motility mediated by the LMP1-FGD4-Cdc42 axis.
(A) Knockdown or (B) re-introduction of FGD4 has no effect on
Rac1 activation. NPC-TW04 cells were co-transfected with
25 mM control or FGD4 siRNA and 1 mg of expression plasmid
for Flag-LMP1 or empty vector. In the case of re-introduction,
2 mg of Myc-FGD4 expression plasmids or Myc vector were added
into the transfection. After 48-h incubation and a following 6-h
serum starvation, cells were lysed for GST-PBD pull-down assays
and analyzed for the level of active Rac1. (C) LMP1-induced
Cdc42 activation is not associated with Rac1 or RhoA activation.
NPC-TW02 cells were co-transfected with control or Cdc42
siRNA duplexes and 1 mg of expression plasmid for Flag-LMP1 or
empty vector. After 48-h incubation and a following 6-h serum
starvation, cells were lysed for GST-PBD and GST-RBD pull-
down assays to analyze the levels of active Rac1 and active RhoA,
respectively. (D) Rac1 and RhoA are not involved in LMP1-
induced cell migration. NPC-TW02 cells were co-transfected with
control, Rac1 or RhoA siRNA duplexes plus a plasmid for Flag-
LMP1 or empty vector. Cells were then re-seeded for transwell
migration assays as detailed above. (E) The knockdown efficiency
was confirmed by Western blot analysis of a portion of cells used in
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antibodies.
(PDF)
Table S1 Functional characterization of FGD4 domains
and their respective effects on LMP1-mediated Cdc42
activation.
(PDF)
Table S2 Clinical information for the nasopharyngeal
biopsies used in the quantitative RT-PCR and immuno-
histochemistry analyses.
(PDF)
Table S3 Primer sets for generating expression vectors.
(PDF)
Table S4 Primer sets for quantitative RT-PCR.
(PDF)
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